Analysis on deficiency of R&D main body′s responsibility in adverse drug reaction monitoring in China

WANG Wenpei,SHAO Rong,CHEN Yongfa
DOI: https://doi.org/10.3969/j.issn.1673-7210.2010.35.053
2010-01-01
Abstract:Objective: To induce relevant department attach importance on the R&D main body′s responsibility in adverse drug reaction monitoring,and provide reference for improving relevant system and regulations.Methods: Study R&D main body′s responsibility in adverse drug reaction monitoring both here and abroad under different drug marketing approval system by means of literature review and comparative analysis etc.Results: The R&D main body′s obligation of monitoring post-marketing drug safety was ignored in China,and to some extent it might hinder the timely detection of potential ADR.The drug marketing approval system in some developed country separated the manufacturing approval and marketing approval,and made it obligate for R&D main body to monitor adverse drug reaction,which can be use for reference.Conclusion: It′s necessity to draw on the experience of developed country,to make it legal for R&D main body to apply for and obtain marketing approval,and to make a sound system of drug safety.
What problem does this paper attempt to address?